ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Jinghai Song
Matched on ORCID iD 0000-0003-1798-3229; OpenAlex author ID A5053034261. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 7
- Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nodes. Last author DOI 10.1007/s13304-025-02075-7↗
- DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression. Last author DOI 10.1096/fj.202402903r↗
- Comment on: "Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma". First author DOI 10.1097/as9.0000000000000248↗
- Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A population-based predictive model. Last author DOI 10.1016/j.pan.2022.01.004↗
- Acidic Tumor Microenvironment Promotes Pancreatic Cancer through miR-451a/MEF2D Axis. Co-author DOI 10.1155/2022/3966386↗
- Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. Last author DOI 10.3389/fonc.2022.975846↗
- Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study. Last author DOI 10.3389/fsurg.2021.804785↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yangyang Zheng · 4 shared papers, 2022–2025 · strength 1.07
- Paper Comment on: "Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal … DOI 10.1097/as9.0000000000000248↗
- Paper Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nod… DOI 10.1007/s13304-025-02075-7↗
- Paper DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progres… DOI 10.1096/fj.202402903r↗
- Jingyong Xu · 5 shared papers, 2021–2025 · strength 0.98
- Paper Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nod… DOI 10.1007/s13304-025-02075-7↗
- Paper DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progres… DOI 10.1096/fj.202402903r↗
- Paper Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. DOI 10.3389/fonc.2022.975846↗
- Haowei Shi · 2 shared papers, 2025 · strength 0.51
- Paper Prognostic significance of three lymph node staging systems in pancreatic cancer with ≤ 12 and > 12 retrieved lymph nod… DOI 10.1007/s13304-025-02075-7↗
- Paper DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progres… DOI 10.1096/fj.202402903r↗
- Weiwei Shao · 3 shared papers, 2021–2022 · strength 0.49
- Paper Acidic Tumor Microenvironment Promotes Pancreatic Cancer through miR-451a/MEF2D Axis. DOI 10.1155/2022/3966386↗
- Paper Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A populatio… DOI 10.1016/j.pan.2022.01.004↗
- Paper Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study. DOI 10.3389/fsurg.2021.804785↗
- Zhenhua Lu · 3 shared papers, 2021–2022 · strength 0.47
- Paper Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer. DOI 10.3389/fonc.2022.975846↗
- Paper Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A populatio… DOI 10.1016/j.pan.2022.01.004↗
- Paper Effects of Total Pancreatectomy on Survival of Patients With Pancreatic Ductal Adenocarcinoma: A Population-Based Study. DOI 10.3389/fsurg.2021.804785↗
- Junmin Wei · 1 shared paper, 2022 · strength 0.19
- Jingyong Xu · 1 shared paper, 2022 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.